About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
Contact
International

June 6 2017

Midterm Outcomes From a Pilot Study
of Percutaneous Deep Vein Arterialization
for the Treatment of No-Option
Critical Limb Ischemia

View the article.

LimFlow Expands Senior Management Team and Opens Silicon Valley Office LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

Related Posts

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia

LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population

Recent Posts

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia
First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia
LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population
Limflow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment

CAUTION: Investigational device. Limited by Federal law to investigational use.:

The LimFlow System is approved for sale in markets regulated by the CE Mark.

©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.